CD8+ cytotoxic T lymphocyte activation via antigen presentation by mature dendritic cell

Activation of **CD8+ cytotoxic T lymphocytes (CTLs)** via antigen presentation by **mature dendritic cells** is a key mechanism of the adaptive immune response[1][5][6][7]. Mature dendritic cells process and present antigenic peptides on MHC class I molecules and provide essential costimulatory signals (CD80, CD86) to naive CD8+ T cells. This leads to clonal expansion, differentiation into cytotoxic effectors, and elimination of infected or malignant cells[2][3][5][7]. This process, also known as **cross-presentation**, is critical for immunity against viruses and tumors and is a major focus in cancer immunotherapy—though it is not a singular molecular target[2][4][6]. **Key molecular components involved include:** - T cell receptor (TCR, on CTLs) - CD8 co-receptor (on CTLs) - Major histocompatibility complex class I (MHC I, on dendritic cells) - Costimulatory molecules such as CD80/CD86 (on dendritic cells) **Summary:** This entry is not a single molecular target but an interaction/process involving multiple molecules and steps. Correct canonical targets derivable from this would be "CD8 molecule," "T cell receptor," "MHC class I," or "CD80/CD86" as the main surface proteins mediating the process[1][3][5][7].

Other names

Cytotoxic T lymphocyte activation by dendritic cellCD8+ T cell primingCD8+ T cell activation via antigen cross-presentation

Enhancement of **antigen presentation** (e.g., DC vaccines) **Immune checkpoint blockade** (preserves or re-invigorates CTL activation by blocking inhibitory signals downstream of this process)